AKRO Projected Dividend Yield
Akero Therapeutics Inc ( NASDAQ : AKRO )Akero Therapeutics is a clinical-stage company developing treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. NASH is a severe form of nonalcoholic fatty liver disease characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, cancer and death. Co.'s primary product candidate, efruxifermin, is an analog of fibroblast growth factor 21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body. 20 YEAR PERFORMANCE RESULTS |
AKRO Dividend History Detail AKRO Dividend News AKRO Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |